Dendritic Cell Vaccination in Allogeneic Stem Cell Recipients: Induction of Human Cytomegalovirus (HCMV)–Specific Cytotoxic T Lymphocyte Responses Even in Patients Receiving a Transplant from an HCMV‐Seronegative Donor | Zendy

Götz Ulrich Grigoleit | Zendy; Markus Kapp | Zendy; Holger Hebart | Zendy; Kerstin Fick | Zendy; Robert Beck | Zendy; Gerhard Jahn | Zendy; Hermann Einsele | Zendy

Open Access

Dendritic Cell Vaccination in Allogeneic Stem Cell Recipients: Induction of Human Cytomegalovirus (HCMV)–Specific Cytotoxic T Lymphocyte Responses Even in Patients Receiving a Transplant from an HCMV‐Seronegative Donor

Author(s) -

Götz Ulrich Grigoleit,

Markus Kapp,

Holger Hebart,

Kerstin Fick,

Robert Beck,

Gerhard Jahn,

Hermann Einsele

Publication year - 2007

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/520538

Subject(s) - human cytomegalovirus , immunology , medicine , vaccination , cytotoxic t cell , cytomegalovirus , dendritic cell , immune system , adverse effect , stem cell , virology , herpesviridae , viral disease , virus , biology , biochemistry , genetics , in vitro

Vaccination with peptide-loaded dendritic cells (DCs) has been shown to be potent immunostimulatory therapy for the management of serious infections. After allogeneic stem cell transplant (SCT), a prolonged and severe immune deficiency often leads to infectious complications. Human cytomegalovirus (HCMV) infection is one such life-threatening complication after allogeneic SCT. A phase 1/2 study including 24 allogeneic SCT recipients at high risk for HCMV disease was performed to analyze the feasibility and efficacy of vaccination with HCMV peptide-loaded DCs. No acute adverse effects were observed, and a significant clinical benefit could be demonstrated in comparison to our historical control group. An induction or expansion of HCMV-specific cytotoxic T lymphocytes was observed in 5 patients after DC vaccination.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research